- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02457026
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in Patients With Neovascular Age-Related Macular Degeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neovascular age-related macular degeneration (NV AMD) remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block vascular endothelial growth factor (VEGF), a major protein mediator of angiogenesis and vascular leakage, have revolutionized treatment of NV AMD. This class of drugs includes the FDA-approved medications ranibizumab (Lucentis ®, Genentech) and aflibercept (Eylea ®, Regeneron), as well as bevacizumab (Avastin ®, Genentech), which is not FDA-approved for the treatment of NV AMD but is used off-label with demonstrated clinical efficacy. However, these therapies are not a cure. Even when effective, the vast majority of NV AMD patients require continued treatment with anti-VEGF drugs indefinitely for the rest of their lives, to sustain stable visual acuity. Further, in spite of continuous monthly anti-VEGF therapy, up to 40-50% of patients demonstrate persistent disease activity (PDA). Patients with persistent disease activity in spite of ongoing anti-VEGF therapy remain at increased risk for long-term vision loss. Persistent disease activity is defined as (1) unresolved intraretinal, subretinal, or sub-retinal pigment epithelium (RPE) fluid or exudation; (2) progressive lesion enlargement and fibrosis; and/or (3) persistent or new hemorrhage. Several large, multicenter, prospective clinical trials have demonstrated ~75% rate of PDA following loading dose therapy (i.e. three consecutive monthly injections), and ~ 40-50% PDA following one year of continued anti-VEGF therapy.
The treatment burden to sustain visual acuity for patients with PDA is especially high, since undertreatment or cessation of therapy assures visual decline. The PIER study assessed the efficacy of quarterly (i.e. every-three-months) anti-VEGF therapy with ranibizumab, following initiation with loading dose therapy. Patients who had resolution of disease activity following loading dose maintained visual acuity gains with subsequent quarterly therapy. In contrast, patients with PDA following loading dose had progressive loss of visual acuity gains when switched to subsequent quarterly therapy. Several subsequent clinical trials (CATT, IVAN, others) have demonstrated that patients with PDA typically require continued monthly therapy to sustain improved visual acuity. Though "do-able" in the short term, indefinite long-term therapy with monthly injections is often impractical for patients and for retina physicians, and as a result, undertreatment occurs with high frequency.
Verteporfin (Visudyne ®, Bausch + Lomb) PDT is an FDA-approved treatment for NV AMD that was initially approved over 10 years ago, prior to the advent of anti-VEGF therapy. As a first-line therapy, verteporfin PDT is much less effective than anti-VEGF therapy in improving vision for NV AMD patients. PDT has been studied as an adjunctive therapy in previously treatment-naïve patients receiving anti-VEGF therapy. It was not found to offer significant visual acuity benefit over anti-VEGF therapy alone, in this population. However, it is unknown whether adjunctive PDT may be effective in improving treatment response in patients with PDA in spite of anti-VEGF therapy. The investigators have performed several retrospective studies of NV AMD patients in the Duke Medical Retina practice to assess the role of adjunctive PDT in cases of PDA. Preliminary results indicate that adjunctive verteporfin PDT reduces disease activity (i.e. decreased fluid and exudation) in patients with PDA, facilitates treatment with fewer anti-VEGF injections (i.e. reduces treatment burden), and reduces risk of subsequent vision loss. However, no studies have prospectively evaluated the efficacy of adjunctive PDT in patients with PDA in spite of anti-VEGF therapy. The present study will assess the efficacy of adjunctive PDT for the treatment of PDA in NV AMD. The investigators will compare administration of anti-VEGF therapy with adjunctive PDT to the standard-of-care treatment approach, anti-VEGF monotherapy administered according to a "treat-and-extend" approach, where the interval between intravitreal injections is as short as every 1 month (approximately 4 weeks) but can be gradually lengthened to the longest interval between treatments that ensures disease quiescence.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Eye Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of either 1) NV AMD with PDA in spite of standard-of-care intravitreal anti-VEGF therapy, either loading dose or maintenance therapy or 2) Clinical diagnosis of NV AMD with Progressive Disease in spite of standard-of-care intravitreal anti-VEGF therapy, either loading dose or maintenance therapy
- Best-corrected visual acuity equivalent of 20/25-20/320
- Able to provide written informed consent
- Presence of discernible choroidal neovascular lesion by ICG angiography
Exclusion Criteria:
- History of porphyria or sensitivity to any component of verteporfin preparation
- Presence of systemic fungal infection or sensitivity to any component of triamcinolone acetonide preparation
- Presence of ocular or periocular infection or sensitivity to any component to aflibercept
- Prior vitrectomy surgery
- Prior thermal laser for macular photocoagulation
- Inability to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days following verteporfin PDT treatment sessions
- Presence of large submacular hemorrhage in association with choroidal neovascular lesion
- Known or suspected allergy to fluorescein and/or indocyanine green
- Known history of open angle glaucoma
- Known history of diabetic macular edema or macular edema attributable to central retinal vein occlusion
- Recent history (within prior 6 months) of cerebrovascular accident (i.e. stroke) or myocardial infarction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adjunctive PDT + Aflibercept
Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3.
At Study Visit 4, participants will have repeat assessment of disease activity.
If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections.
If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6.
Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months.
If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
|
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Other Names:
Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
Other Names:
Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
Other Names:
|
Active Comparator: Aflibercept Alone
Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3.
At Study Visit 4, participants will have repeat assessment of disease activity.
From Study Visit 4 onwards, aflibercept will be administered according to a "treat-and-extend" strategy.
If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially "extended" from every 28 days to every 42 days.
If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments.
For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time.
|
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of individuals with resolution or major reduction in PDA
Time Frame: up to 8 weeks after loading dose
|
up to 8 weeks after loading dose
|
Percentage of individuals with sustained visual acuity
Time Frame: 1 year after loading dose
|
1 year after loading dose
|
Average number of aflibercept injections
Time Frame: 1 year after loading dose
|
1 year after loading dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of case with progressive disease on therapy
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Mean change in central foveal thickness by SD-OCT
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Mean change in best-corrected ETDRS visual acuity from baseline
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Percentage of participants with 2-line ETDRS visual acuity gain
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Percentage of participants with 2-line ETDRS visual acuity loss
Time Frame: 6 months post-PDT treatment
|
6 months post-PDT treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Priyatham Mettu, MD, Duke University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Wet Macular Degeneration
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Photosensitizing Agents
- Dermatologic Agents
- Verteporfin
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
- Aflibercept
Other Study ID Numbers
- Pro00063930
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Iconic Therapeutics, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
Clinical Trials on Aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms, Lung | Pulmonary DiseasesUnited States, France, Canada
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary